Human Immunoglobulin (Ph4) For Intravenous Injection (COVID-19) Market held USD 43205.8 million in 2020 and is to grow with a CAGR of 12.5% from 2020-2030. The glycoprotein molecules in white blood cells are immunoglobulins. Human immunoglobulin (pH4) is a colorless / clear, or light-yellow solution for intravenous injection. It that show opalescence but with no turbidity. Immunoglobulin treatment applies to a combination of immunoglobulins being used to manage different health problems. Such disorders involve form of infections where there is no more precise immunoglobulin available, such as certain HIV / AIDS and measles outbreaks, polyneuropathy, and more. These formulations are delivered straight into the patient's vein. Human blood plasma is used in the production of human immunoglobulin, and these contain antibodies to combat many viruses.
Market Dynamics and Factors:
Key human immunoglobulin for intravenous injection market trends on emerging developments include outbreaks of infectious illness, elevated incidence of chronic lymphocytic leukemia and increasing appetite for immune globulin items. According to the American Cancer Society, in 2020 about 60,530 new cases of leukemia will be detected in the US, out of which 21,040 new cases of chronic leukemia (CLL) will be identified. Similarly, about 3,500 new cases of chronic lymphocytic leukemia (CLL) have been diagnosed in the UK in 2017, according to Cancer Study UK. Additionally, growing cases of coronavirus globally will further enhance the growth of global human immunoglobulin (ph4) for intravenous injection (covid-19) market growth.
Market Segmentation:
Based on the type, the human immunoglobulin (ph4) for intravenous injection (COVID-19) market industry is segmented into IgG, IgA, IgM. On the basis of disease, the market is categorized into kawasaki disease, immune-mediated thrombocytopenia, primary immunodeficiency disease, Covid-19, b chronic lymphocytic leukemia(b-cll)). Based on distribution channel, the market is divided into hospital, retail, online. Geographical breakdown and analysis of each of the aforementioned segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographic Analysis:
The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market demand is expected to witness significant growth potential in forecast period owing to spurt in disease outbreaks such as coronavirus and the growing prevalence of chronic lymphocytic leukemia. In addition, the immune globulin (IG) drugs is projected to fuel market growth in human immunoglobulin (ph4) for intravenous injection (COVID-19). For starters, the U.S. on 12 August 2019 The Food and Drug Administration (FDA) reported that demand for immune globulin products has risen in recent years, and that there is a lack of Immune Globulin (Subcutaneous) (IGSC) and Immune Globulin (IGIV) products throughout the United States. The U.S. Food and Drug Administration works closely with manufacturers of various (intravenous) immune globulin (IGIV) products to help mitigate the supply situation.
Competitive Scenario:
Global human immunoglobulin (ph4) for intravenous injection (covid-19) demand is highly competitive, consists of a few major players. In terms of human immunoglobulin (ph4) for intravenous injection (covid-19) market share, few of the major players currently dominate the market. Key players enhancing the global human immunoglobulin (ph4) for intravenous injection (covid-19) market size include ADMA Biologics, Inc., Hualan Biological Engineering Inc., Baxter International Inc., CSL Behring, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Bayer AG, Grifols, S.A., Octapharma AG, China Biologic Products, Inc., Takeda Pharmaceutical Company Limited, Boya Bio-Pharmaceutical Group Co., Ltd., and Sinopharm Group Co., Ltd.
Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Report Scope
| Report Attribute | Details |
| Analysis Period | 2020–2030 |
| Base Year | 2021 |
| Forecast Period | 2022–2030 |
| Market Size Estimation | Million (USD) |
| Growth Rate (CAGR%) | 12.5 % |
|
| By Type (IgG, IgA, IgM), By Disease (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL)), By Distribution Channel (Hospital, Retail, Online) |
| Geographical Segmentation | North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), South America (Brazil, Argentina, Rest of SA), MEA (UAE, Saudi Arabia, South Africa) |
| Key Companies Profiled | ADMA Biologics, Inc., Hualan Biological Engineering Inc., Baxter International Inc., CSL Behring, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Bayer AG, Grifols, S.A., Octapharma AG, China Biologic Products, Inc., Takeda Pharmaceutical Company Limited, Boya Bio-Pharmaceutical Group Co., Ltd., and Sinopharm Group Co., Ltd. |
